-
Uncategorized5 months agoBreaking through the undruggable barrier with TPDs
Alex Bentley, an 1851 Industrial Fellow working with GSK and the University of Strathclyde, discusses how his research into protein degraders will benefit drug discovery efforts...
-
Uncategorized5 months agoSTAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where...
-
Uncategorized5 months ago
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
-
Uncategorized5 months ago
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
-
Uncategorized5 months agoSTAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion
In a move that will grow its oncology pipeline, Gilead Sciences is spending more than $3 billion to buy the German biotech Tubulis, the companies said...
-
Uncategorized5 months ago
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma...
-
Uncategorized5 months ago
BioNTech to shutter Singapore HQ after ‘comprehensive review’
BioNTech to shutter Singapore HQ after 'comprehensive review'
-
Uncategorized5 months ago
CRO Fortrea launches AI-powered solution to improve trial efficiency
Fortrea is expanding its capabilities with a suite of AI-powered technologies designed to automate workflows, streamline oversight and improve productivity for trial sponsors.
-
Uncategorized5 months agoSTAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis....
-
Uncategorized5 months agoOpinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI
About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time...
Novo’s Denecimig Demonstrates Tolerability After Switch from Emicizumab in FRONTIER5 Study of People with Haemophilia A as Published in the Journal of Thrombosis and Haemostasis
Animal Rule Information
Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
